Explore

Streams

Products

About Index

Index

By TNW

Exelixis

3950

Exelixis

At Exelixis, our vision is to build a global biopharmaceutical company providing new treatment options to cancer patients.

Founded

1994

Follow us

Also headquartered in San Francisco

Companies in the same industry

Alexa global traffic share

Terms of Service Privacy Policy Cookie Statement API Integrations Plans & Pricing

Built with ❤︎ by Datalicious ©2021
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

Overview

Team Size

200+

Employees

Location

San Francisco , United States

Headquarters

Explore San Francisco

Roche-Exelixis Study Fails as Mixed Year Continues For Cancer Drug Combos

Exelixis, Inc. Setting New Standard of Care

Exelixis, Inc. Gets Some ASCO Love

Exelixis, Inc. Rides Cabometyx's Coattails to Big Gains in May

These 2 Billionaires Are Dumping Exelixis' Stock. Should You?

Stock markets

This New Data Could Push Exelixis' Cabometyx Over $1 Billion in Peak Annual Sales

Exelixis, Inc. Prepares for Blastoff

Health Announcements

2 Big Reasons Why Shares of Exelixis, Inc. Soared 15% in April

Health Stock markets Earnings

Better Buy: Exelixis, Inc. vs. Roche

Exelixis, Inc.'s Cabometyx Approved: Let the Kidney Cancer Battle Begin!

Exelixis, Inc.'s EKG-Like Stock Chart Hits a Low Spot

Stock markets Health

Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb

Why Exelixis' Stock Dropped 10% on Tuesday

Exelixis, Inc. Partnering Before Approval

Exelixis Inc. Stock Was Throttled in February -- Here's Why

On Comeback Trail, Exelixis Reels In $200M Deal For Cancer Drug

Health Earnings

Emotional Investing Deflates Exelixis, Inc. in January

Why Exelixis, Inc. Rocketed Higher on Friday

Stock markets Health

Exelixis, Inc. Nearly Quadrupled in 2015 -- Here's Why --

Why Exelixis, Inc. Is Trading Higher Today --

Stock markets Health